What is da EPOCH chemo?

What is da EPOCH chemo?

What is da EPOCH chemo?

An abbreviation for a chemotherapy combination used to treat certain types of non-Hodgkin lymphoma. It includes the drugs etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), and rituximab.

How often is R-EPOCH given?

DA-EPOCH-R is typically repeated every 21 – 28 days. This is known as one Cycle. Each cycle may be repeated up to 8 times, depending upon the stage of the disease.

What is the R in R-CHOP chemo?

R-CHOP is named for the initials of the five drugs. The R comes from rituximab, which is not a chemotherapy drug but is composed of man-made antibodies that help your immune cells destroy cancerous tumors. The addition of rituximab replaced a longtime therapy called CHOP that didn’t work very well and was highly toxic.

How is EPOCH given?

Initial infusion: Start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated. In the absence of an initial infusion reaction, for subsequent infusions, administer 20% of the total dose over the first 30 minutes and the remaining 80% over 60 minutes, as tolerated.

What is Rice chemotherapy for lymphoma?

How does RICE (or R-ICE) chemotherapy work? Each of the medications in the RICE chemotherapy regimen are designed to kill cancerous lymphocytes, a type of white blood cell. Rituixmab binds to the surface of the cancer cell, while ifosfamide, carboplatin, and etoposide all enter the cancer cell and attack its DNA.

Is R-CHOP chemotherapy successful?

Despite its aggressive disease course, ∼50% to 70% of patients may be cured by current standard of care consisting of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.

How effective is R epoch?

The patients received DA-EPOCH-R administered with CNS prophylaxis for six cycles. Primary endpoints included event-free (EFS) and overall survival (OS). The overall response rate was 87 percent, and 74 percent achieved a complete response. The 48-month EFS and OS were 71 percent and 77 percent respectively.